ARYx Therapeutics

Sector(s): Pharmaceutical
Location: Fremont, CA 
Status: Public

The ARYx mission is to make proven therapies safer. By applying its retrometabolic approach to pharmaceutical discovery and development, ARYx intends to serve patients by fundamentally improving the safety of oral therapies in large, chronic markets while maintaining their efficacy. To optimize shareholder value, ARYx's goal is to be a profitable company with a continuing pipeline of products, balancing risk against rewards through collaborations with pharmaceutical partners. In November 2007 the company completed an initial public offering led by Morgan Stanley and trdes under the NASDAQ symbol ARYX.